Best Nanotechnology Stocks To Follow Now – June 13th

OSI Systems, NVE, and Clene are the three Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Nanotechnology stocks are shares of publicly traded companies that research, develop and commercialize materials, devices or processes at the nanoscale. These firms span industries like medicine, electronics and energy, and their shares often appeal to investors seeking high-growth opportunities—albeit with higher volatility due to the emerging nature of the technology. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

Shares of OSIS stock traded down $5.59 during trading hours on Friday, hitting $230.99. 142,281 shares of the company’s stock traded hands, compared to its average volume of 198,327. The stock’s 50 day simple moving average is $213.05 and its 200 day simple moving average is $195.44. OSI Systems has a 12 month low of $129.18 and a 12 month high of $241.64. The company has a quick ratio of 1.25, a current ratio of 1.88 and a debt-to-equity ratio of 0.56. The stock has a market cap of $3.88 billion, a PE ratio of 29.68, a price-to-earnings-growth ratio of 1.81 and a beta of 1.28.

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

NVE stock traded down $2.53 during midday trading on Friday, reaching $69.40. The stock had a trading volume of 26,214 shares, compared to its average volume of 32,809. The company has a market capitalization of $335.69 million, a P/E ratio of 22.39 and a beta of 1.15. NVE has a 12 month low of $51.50 and a 12 month high of $89.98. The company has a fifty day moving average price of $65.14 and a two-hundred day moving average price of $70.61.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

CLNN stock traded up $0.05 during trading on Friday, reaching $4.13. The stock had a trading volume of 62,397 shares, compared to its average volume of 88,323. The company has a market capitalization of $37.10 million, a price-to-earnings ratio of -0.78 and a beta of 0.49. The company’s 50 day moving average is $3.08 and its two-hundred day moving average is $3.99. Clene has a one year low of $2.28 and a one year high of $8.60.